| Literature DB >> 25019558 |
Abstract
The docking methods used in structure-based virtual database screening offer the ability to quickly and cheaply estimate the affinity and binding mode of a ligand for the protein receptor of interest, such as a drug target. These methods can be used to enrich a database of compounds, so that more compounds that are subsequently experimentally tested are found to be pharmaceutically interesting. In addition, like all virtual screening methods used for drug design, structure-based virtual screening can focus on curated libraries of synthesizable compounds, helping to reduce the expense of subsequent experimental verification. In this review, we introduce the protein-ligand docking methods used for structure-based drug design and other biological applications. We discuss the fundamental challenges facing these methods and some of the current methodological topics of interest. We also discuss the main approaches for applying protein-ligand docking methods. We end with a discussion of the challenging aspects of evaluating or benchmarking the accuracy of docking methods for their improvement, and discuss future directions.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25019558 PMCID: PMC6270832 DOI: 10.3390/molecules190710150
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
The percent distribution of the gene families targeted by FDA-approved drugs as of 2005. These statistics were compiled by Overington et al. from FDA data in 2005 [3].
| Portion of Drugs | Family of Drug Target |
|---|---|
| 26.8% | Rhodopsin-like GPCRs |
| 13.0% | Nuclear receptors |
| 7.9% | Ligand-gated ion channels |
| 5.5% | Voltage-gated ion channels |
| 4.1% | Penicillin-binding protein |
| 3.0% | Myeloperoxidase-like |
| 2.7% | Sodium: neurotransmitter symporter family |
| 2.3% | Type II DNA topoisomerase |
| ≈35% | (other) |